SIMPLAAFY Clinical Trial

Inclusion Criteria: * Subject is of legal age to participate in the study per the laws of their respective geography. * Subject is an acceptable candidate for a WATCHMAN FLX Pro device per the approved Instructions for Use. * Subject is deemed to be suitable for all protocol defined drug regimens in the control and both test arms. * The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial. * The subject is able and willing to return for required follow-up visits and examinations. Exclusion Criteria: * Subject's device implant procedure was aborted (i.e., failed implant). * Subject has a device margin residual leak \> 0mm at time of implant. * Occurrence of complications (major bleeding, systemic embolism, stroke, pericardial effusion requiring intervention) during the implant procedure, post-procedure, or prior to randomization. * Subject has a contraindication to one of the three protocol defined drug regimens. * Subject requires long-term anticoagulation therapy for reason other than AF-related stroke risk reduction or requires chronic P2Y12 inhibitor therapy. * Subject has known history of severe liver disease including cirrhosis with a Child-Pugh classification C or D. * Subject with known hypercoagulability disorder, mechanical heart valve, rheumatic heart disease, or recurrent deep vein thrombosis. * Subject has intracardiac thrombus, LAA sludge, or dense spontaneous echo contrast (SEC) obse…